Patent ID: 6613802
Filing Date: 2003-09-02
Classification: A61K,A61P,Y10S

Abstract:
A method of treating hyperuricemia in a mammal, comprising administering to said mammal a therapeutically effective amount of a composition comprising the (âˆ’) enantiomer of a compound of Formula I, wherein:R is a member selected from the group consisting of a hydroxy, lower aralkoxy, di-lower alkylamino-lower alkoxy, lower alkanamido lower alkoxy, benzamido-lower alkoxy, ureido-lower alkoxy, Nâ€²-lower alkyl-ureido-lower alkoxy, carbamoyl-lower alkoxy, halophenoxy substituted lower alkoxy, carbamoyl substituted phenoxy, carbonyl-lower alkylamino, N,N-di-lower alkylamino-lower alkylamino, halo substituted lower alkylamino, hydroxy substituted lower alkylamino, lower alkanolyloxy substituted lower alkylamino, ureido, and lower alkoxycarbonylamino; and each X is independently a halogen; or a pharmaceutically acceptable salt thereof, wherein the composition contains the (âˆ’) enantiomer of the compound in an enantiomeric excess of at least 80% relative to the (+) enantiomer of the compound, and wherein the composition exhibits a reduced inhibition of cytochrome P450 2C9 relative to a composition having ab out 0% enantiomeric excess of the(âˆ’) enantiomer.